RxDoctor Payments Data

Linda Pettit

Psychiatric/Mental Health, Adult · Centerville, OHNPI 1063593523

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $311 and has fallen 84.7% since, to $48 in 2024.

$747in general payments, 2019–2025

Across 43 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$136
  • Vanda Pharmaceuticals Inc.$108
  • Corium, LLC$97
  • Teva Pharmaceuticals USA, Inc.$71
  • Sunovion Pharmaceuticals Inc.$50
  • Adlon Therapeutics L.p.$46
  • plus $239 from 11 others

What the payments were for

  • Food & beverage$747100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$747 in reported general payments places this provider in the 55th percentile of 42 psychiatric/mental health, adult providers in Ohio.

See all psychiatric/mental health, adult providers in Ohio

Medicare billing

Part B allowed, 2024
$4,865
Medicare patients
22
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl19$27,735
Lurasidone Hcl18$11,104
VascepaIcosapent Ethyl39$7,178
Quetiapine Fumarate78$1,380
Lamotrigine100$1,113
Fluoxetine Hcl114$998
Perphenazine22$839
Risperidone69$593
Benztropine Mesylate44$522
Duloxetine Hcl18$497
Olanzapine31$478
Aripiprazole33$404
Escitalopram Oxalate16$382
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$354
Clonidine Hcl46$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$136$27,73519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 42 psychiatric/mental health, adult providers in Ohio.

Other psychiatric/mental health, adult in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →